Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis

doi:10.5493/wjem.v14.i4.98543

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (543)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

HTML

335

Figures (1-3)

Tables (1-1)

Sum=367

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=81

Publishing Process of This Article

Item

Count

Browse

Download

Sum=37

Dec 20, 2024 (publication date) through Nov 6, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Exp Med. Dec 20, 2024; 14(4): 98543
Published online Dec 20, 2024. doi: 10.5493/wjem.v14.i4.98543

Table 1 Baseline characteristics of included studies

Ref.	Study design	Age (years)	Total patients (n)	Males/females	Statin users	Non-users	Cirrhosis	No cirrhosis	Follow-up (years)
Zou et al[51]	Cohort	52.1 ± 14.7	272430	126804/145626	73384	199046	34257	238173	727390 person-year
Pinyopornpanish et al[50]	Cohort	59 ± 10.4	1072	432/640	440	632	950	122	4326 person-year
German et al[49]	Case-control	64.3 ± 13.1	102	66/36	40	62	93	9	Not applicable
Lee et al[48]	Cohort	52.7 (41.6-64.4)	18080	9502/8578	6382	11698	0	18080	6.32 (3.04-10.10)

Citation: Tarar ZI, Farooq U, Inayat F, Basida SD, Ibrahim F, Gandhi M, Nawaz G, Afzal A, Chaudhary AJ, Kamal F, Ali AH, Ghouri YA. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis. World J Exp Med 2024; 14(4): 98543
URL: https://www.wjgnet.com/2220-315x/full/v14/i4/98543.htm
DOI: https://dx.doi.org/10.5493/wjem.v14.i4.98543